Scaling AAV manufacturing across fixed-bed bioreactors: lessons from Novartis (APAC)
A Khorran, X Cui, D Knutson
A scalable CAR-T cell manufacturing workflow producing 100+ doses per batch
Pierre Springuel, PhD, Rukmini Ladi
Improved gene delivery and T Cell editing using cell free DNA and novel non viral delivery solutions
Claire Gueguen, PhD, Peter Archibald, PhD
Cell-derived nanoparticles: a new paradigm for CAR-T cell activation and manufacturing
P Moura, B Shy, K Li et al.